Taysha Gene Therapies
TSHA
191 hedge funds and large institutions have $1.21B invested in Taysha Gene Therapies in 2026 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 69 increasing their positions, 49 reducing their positions, and 35 closing their positions.
356% more call options, than puts
Call options by funds: $1.61M | Put options by funds: $354K
41% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 49
0% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 35
2% less funds holding
Funds holding: 195 → 191 (-4)
5.73% less ownership
Funds ownership: 98.2% → 92.47% (-5.7%)
19% less capital invested
Capital invested by funds: $1.48B → $1.21B (-$274M)
50% less funds holding in top 10
Funds holding in top 10: 6 → 3 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$40.3M |
| 2 |
VPC
Vestal Point Capital
New York
|
+$19.8M |
| 3 |
CC
Casdin Capital
New York
|
+$8.14M |
| 4 |
SG Americas Securities
New York
|
+$6.49M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.69M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$15.8M |
| 2 |
Barclays
London,
United Kingdom
|
-$12.7M |
| 3 |
RI
RTW Investments
New York
|
-$12.6M |
| 4 |
AAA
Affinity Asset Advisors
New York
|
-$10.7M |
| 5 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$10.6M |
TSHA Hedge Fund Activity: Q1 2026 in Review
191 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in Taysha Gene Therapies (TSHA) for Q1 2026, worth a combined $1.21B — down 19% from $1.48B a quarter earlier.
Fund positioning in TSHA was balanced in Q1 2026: 35 funds opened new positions, 35 closed out, 69 added to existing stakes and 49 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $40.3M. The largest seller was Point72 Asset Management, cutting an estimated $15.8M.
- 191 institutional investors held Taysha Gene Therapies (TSHA) as of Q1 2026, down from 195 in Q4 2025.
- Funds reported $1.21B of Taysha Gene Therapies stock for Q1 2026, down 19% quarter-over-quarter.
- 35 funds opened new Taysha Gene Therapies positions in Q1 2026 and 35 closed out, a net change of 0 holders.
- The largest Taysha Gene Therapies buyer in Q1 2026 was Goldman Sachs, an estimated $40.3M added.
- The largest Taysha Gene Therapies seller in Q1 2026 was Point72 Asset Management, an estimated $15.8M sold.
Based on aggregated 13F filings for Q1 2026.